Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 6, 2013, Pages 1095-1101

  Gage, Julia C ^a   Schiffman, Mark ^a   Solomon, Diane ^a   Wheeler, Cosette M ^b   Gravitt, Patti E ^c   Castle, Philip E ^d   Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATYPICAL SQUAMOUS CELL OF UNDETERMINED SIGNIFICANCE; CANCER GRADING; CANCER SCREENING; CARCINOGENESIS; COLPOSCOPY; CONTROLLED STUDY; CYTOPATHOLOGY; DISEASE MARKER; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; PAPOVAVIRUS; PELVIC EXAMINATION; PRECANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CYTODIAGNOSIS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PROGNOSIS; RISK FACTORS; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84879014443     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1455     Document Type: Article

References (17)

1. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 2011;136:578-86.
2. Wheeler CM, Hunt WC, Schiffman M, Castle PE. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006;194:1291-9. (Pubitemid 44630975)
3. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102:1478-88.
4. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9. (Pubitemid 41417924)
5. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005;97:1066-71. (Pubitemid 41417923)
6. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147-72.
7. Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol 2000;44: 726-42.
8. ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393-400.
9. ASCUS-LSILTraige Study (ALTS) Group. Results of a randomized trialon the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-92.
10. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 2008;46:109-17.
11. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, et al. Determinants of genital human papillomavirus detection in a U.S. population. J Infect Dis 2001;183:1554-64. (Pubitemid 32466692)
12. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61. (Pubitemid 30043317)
13. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009;10:321-2.
14. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007;197:356 e1-6.
15. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011;135:468-75.
16. Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, et al. Clinical validation of the Cervista HPVHR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010;118:116-22.
17. Einstein MH, Garcia FA, Mitchell AL, Day SP. Age-stratified performance of the Cervista HPV 16/18 genotyping test in women with ASCUS cytology. Cancer Epidemiol Biomarkers Prev 2011;20:1185-9.